Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04173065

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH — VOYAGE  

NASH - Nonalcoholic Steatohepatitis Clinical Trial

Official title:
VK2809 A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects With Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosis

Clinical Trial Summary

The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This visit represents the End-of-Study Visit (Week 56 Visit). Three hundred thirty-seven subjects will be enrolled into five treatment arms and there will be an equal distribution of males and females in each treatment arm. Subjects will be stratified by gender, fibrosis stage, and diabetes status.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Fatty Liver
  • NASH - Nonalcoholic Steatohepatitis
  • Non-alcoholic Fatty Liver Disease
Clinical Trial Details
NCT number NCT04173065
Study type Interventional
Source Viking Therapeutics, Inc.
Contact
Status Completed
Phase Phase 2
Start date November 15, 2019
Completion date January 26, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Active, not recruiting NCT05479721 - LITMUS Imaging Study
Not yet recruiting NCT05120557 - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH N/A
Recruiting NCT04976283 - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver Phase 4
Completed NCT02784444 - A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Phase 2
Not yet recruiting NCT05499949 - The Franciscus Obesity NASH Study
Completed NCT04321343 - Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Not yet recruiting NCT03648554 - Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Phase 4
Completed NCT04972396 - ALT-801 DDI Study in Healthy Volunteers Phase 1
Completed NCT03748628 - Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects Phase 1
Enrolling by invitation NCT05195944 - Semaglutide vs Sitagliptin Phase 4
Completed NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Terminated NCT03669133 - Vitamin E for NASH Treatment in HIV Infected Individuals Phase 2
Completed NCT04066400 - Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis N/A
Completed NCT03536650 - Effect of DMR in the Treatment of NASH N/A
Completed NCT03783897 - A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects Phase 1
Completed NCT04618744 - A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH) Phase 2
Active, not recruiting NCT05338034 - Phase 2a Study of HPG1860 in Subjects With NASH Phase 2
Active, not recruiting NCT04653103 - NASH in Subjects With Different Classes of Obesity